The concomitant presence of lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients

Abstract

Nojima et al (2002) recently reported the co-existence of lupus anticoagulant (LA) and anti-prothrombin antibodies as a risk factor for the prevalence of acquired activated protein C resistance (APCR) in systemic lupus erythematosus (SLE) patients, which was furthermore associated with venous thromboembolism. The acquired APCR phenotype occurs in the absence of the factor V (FV) Leiden mutationand has been described among patients with antiphospholipid antibodies (APA).There is no clear information about which antibodies are involved in this phenotype. However, an in vitro effect of theanti-b2-glycoprotein I (ab2GPI) antibodies on the response to activated protein C (APC) has been described (Matsuda et al, 1995; Martinuzzo et al, 1996; Galli et al, 1998).We evaluated whether the presence of ACA immunoglobulin (Ig)G and ab2GPI IgG was associated with acquired APCR in 24 LA patients with primary antiphospholipid syndrome.